Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.65 |
| ▸ | DRD1 | P21728 | 5/20 | 0.65 |
| ▸ | DRD5 | P21918 | 5/20 | 0.65 |
| ▸ | DRD3 | P35462 | 4/20 | 0.65 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19599365 | 0.89 | DRD2 (0.74) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL21195968 | 0.85 | DRD2 (0.75) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL30391211 | 0.85 | DRD2 (0.75) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL3199731 | 0.82 | DRD2 (0.51) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL24425272 | 0.80 | MAOA (0.55) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL29876336 | 0.80 | MAOA (0.55) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL17721296 | 0.79 | MAOA (0.59) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL12363802 | 0.79 | MAOA (0.59) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL29507212 | 0.79 | MAOA (0.59) | DRD2DRD1DRD5DRD3MAOA | |
| SCHEMBL20869490 | 0.78 | DRD2 (0.49) | DRD2DRD1DRD5DRD3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-112745335-B | Tri-heterocyclic compound and application thereof | 武汉誉祥医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-113024544-B | Cyano-containing heterocyclic compound and application thereof | 武汉誉祥医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-6096752-A | Method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives | HEINONEN PETRI (FI) | 2000-08-01 | — | — | US | disclosed |
| US-5912342-A | SYNTHESIS OF COMBINATORIAL LIBRARIES BY COMPUTER CONTROLLED ROBOT | HEINONEN PETRI (FI) | 1999-06-15 | — | — | US | disclosed |
| US-4847264-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4632927-A | ANTISECRETORY, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0113782-A4 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES. | RORER INTERNAT OVERSEAS INC (US) | 1986-03-18 | — | — | EP | disclosed |
| US-4520025-A | ANTIULCER AND ANTISECRETORY AGENTS: | WILLIAM H. RORER, INC. (US) | 1985-05-28 | — | — | US | disclosed |
| EP-0135084-A2 | Tetrahydroisoquinolincarbamic-acid esters, process for their preparation and their use as pesticides | BAYER AG (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0113782-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1984-07-25 | — | — | EP | disclosed |
| WO-1984000544-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084429-B2 | Fused ring compounds | KRAS, NRAS, HRAS | DRD2 4811/4885DRD1 4832/4885DRD5 4783/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | DRD2 4811/4885DRD1 4832/4885DRD5 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.